Lupin Ltd
NSE:LUPIN
Lupin Ltd
NSE:LUPIN
Price:
2 347.6
INR
0.68%
Market Closed
Market Cap:
₹1.1T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Lupin Ltd
NSE:LUPIN
|
IN |
|
WSP Global Inc
TSX:WSP
|
CA |
Multiples-Based Value
The Multiples-Based Value of one
LUPIN
stock under the Base Case scenario is
2 358.76
INR.
Compared to the current market price of 2 347.6 INR,
Lupin Ltd
is
Fairly Valued.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LUPIN
Multiples-Based Value
Base Case
2 358.76
INR
Fairly Valued
Multiples Across Competitors
LUPIN Competitors Multiples
Lupin Ltd Competitors
Lupin Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Lupin Ltd
NSE:LUPIN
|
1.1T INR | 4.1 | 23.1 | 14.7 | 17.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13.1 | 41.4 | 28 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.6 | 16.2 | 10 | 12.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20.3 | 7.8 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
